10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

TXNIP Antibody(N-term)

Affinity Purified Rabbit Polyclonal Antibody (Pab)
Catalog # AP19855a

Specification

TXNIP Antibody(N-term) - Product Information

Application	**WB,E**
Primary Accession	Q9H3M7
Other Accession	Q5M7W1, Q8BG60, NP_006463.3
Reactivity	**Human**
Predicted	**Mouse, Rat**
Host	**Rabbit**
Clonality	**Polyclonal**
Isotype	**Rabbit IgG**
Calculated MW	**43661**
Antigen Region	**1-30**

TXNIP Antibody(N-term) - Additional Information

Gene ID 10628

Other Names
Thioredoxin-interacting protein, Thioredoxin-binding protein 2, Vitamin D3 up-regulated protein 1, TXNIP, VDUP1

Target/Specificity
This TXNIP antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 1-30 amino acids from the N-terminal region of human TXNIP.

Dilution
WB~~1:1000
E~~Use at an assay dependent concentration.

Format
Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.

Storage
Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions
TXNIP Antibody(N-term) is for research use only and not for use in diagnostic or therapeutic procedures.

TXNIP Antibody(N-term) - Protein Information

Name TXNIP

Synonyms VDUP1

Function May act as an oxidative stress mediator by inhibiting thioredoxin activity or by limiting its bioavailability (PubMed:17603038). Interacts with COPS5 and restores COPS5-induced suppression of CDKN1B stability, blocking the COPS5-mediated translocation of CDKN1B from the nucleus to the cytoplasm (By similarity). Functions as a transcriptional repressor, possibly by acting as a bridge molecule between transcription factors and corepressor complexes, and over-expression will induce G0/G1 cell cycle arrest (PubMed:12821938). Required for the maturation of natural killer cells (By similarity). Acts as a suppressor of tumor cell growth (PubMed:18541147). Inhibits the proteasomal degradation of DDIT4, and thereby contributes to the inhibition of the mammalian target of rapamycin complex 1 (mTORC1) (PubMed:21460850).

Cellular Location
Cytoplasm {ECO:0000250|UniProtKB:Q8BG60}.

TXNIP Antibody(N-term) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

TXNIP Antibody(N-term) - Images



TXNIP Antibody (N-term) (Cat. #AP19855a) western blot analysis in NCI-H292 cell line lysates (35ug/lane).This demonstrates the TXNIP antibody detected the TXNIP protein (arrow).

10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999



All lanes : Anti-TXNIP Antibody (N-term) at 1:1000 dilution Lane 1: LNCaP whole cell lysate Lane 2: MCF-7 whole cell lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 44 kDa Blocking/Dilution buffer: 5% NFDM/TBST.

TXNIP Antibody(N-term) - Background

TXNIP may act as an oxidative stress mediator by inhibiting thioredoxin activity or by limiting its bioavailability. Interacts with COPS5 and restores COPS5-induced suppression of CDKN1B stability, blocking the COPS5-mediated translocation of CDKN1B from the nucleus to the cytoplasm. Functions as a transcriptional repressor, possibly by acting as a bridge molecule between transcription factors and corepressor complexes, and over-expression will induce G0/G1 cell cycle arrest. Required for the maturation of natural killer cells.

TXNIP Antibody(N-term) - References

Zhuo de, X., et al. J. Biol. Chem. 285(41):31491-31501(2010)
Kwon, H.J., et al. J. Immunol. 185(7):3980-3989(2010)
Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)
Yu, F.X., et al. J. Biol. Chem. 285(33):25822-25830(2010)
Cadenas, C., et al. Breast Cancer Res. 12 (3), R44 (2010) :